In vivo studies with nintedanib demonstrated reduced xenograft growth as well as reduced number of activated CAFs expressing α-SMA, and that combination therapy with nintedanib and gemcitabine against CAFs and ICC cells had the strongest inhibition of tumor growth. Here, ACTA1 is linked to intrahepatic cholangiocarcinoma.